IP Library Granted Patent US 9,402,813
Granted Patent B2
US 9,402,813 · App. 14/748,605 · Granted Aug 2, 2016

Pharmaceutical compositions

Inventor: Paul Bosse (Jupiter, FL)
Assignee: LOCL PHARMA, INC.
A61K9/209A61K9/20A61K9/2086A61K31/167A61K31/485A61K31/5415A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,402,813
App. No.
14/748,605
Granted
Aug 2, 2016
Kind
B2
Abstract

Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic.

Claims (32)

1. A solid oral pharmaceutical composition for treatment of pain, and reduction or prevention of nausea or vomiting associated with an opioid analgesic, comprising:

a layer formulated for immediate-release that comprises an antiemetic; and

a layer formulated for controlled-release that comprises an opioid analgesic and a non-opioid analgesic,

wherein the opioid analgesic, the non-opioid analgesic, and the antiemetic are present in a ratio by weight of (1 to 2):(40 to 45):(1 to 2), respectively, and

wherein the solid oral pharmaceutical composition provides an effective amount of the antiemetic to reduce or prevent nausea associated with the opioid analgesic or vomiting associated with the opioid analgesic in a subject in need thereof, and an effective amount of the opioid analgesic and the non-opioid analgesic to treat pain in the subject in need thereof.

2. The solid oral pharmaceutical composition of claim 1 , wherein the opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof, or oxycodone or a pharmaceutically acceptable salt thereof.

3. The solid oral pharmaceutical composition of claim 2 , wherein the hydrocodone or the pharmaceutically acceptable salt thereof, or the oxycodone or the pharmaceutically acceptable salt thereof is present in an amount of 1-20 mg.

4. The solid oral pharmaceutical composition of claim 2 , wherein the opioid analgesic is hydrocodone or the pharmaceutically acceptable salt thereof, and is present in an amount of about 1-15 mg.

5. The solid oral pharmaceutical composition of claim 1 , wherein the opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof, and is present in an amount of about 7.5 mg.

6. The solid oral pharmaceutical composition of claim 1 , wherein the opioid analgesic is hydrocodone or the pharmaceutically acceptable salt thereof, and is present in an amount of 5 mg.

7. The solid oral pharmaceutical composition of claim 1 , wherein the opioid analgesic is hydrocodone bitartrate and is present in an amount of about 7.5 mg.

8. The solid oral pharmaceutical composition of claim 1 , wherein the opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof, and is present in an amount of about 7.5 mg.

9. The solid oral pharmaceutical composition of claim 1 , wherein the opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof, and is present in an amount of 10 mg.

10. The solid oral pharmaceutical composition of any one of claims 1 , 2 , 3 , 4 , or 6 , wherein the opioid analgesic is hydrocodone bitartrate.

11. The solid oral pharmaceutical composition of any one of claims 1 , 2 , 3 , 8 or 9 , wherein the opioid analgesic is oxycodone hydrochloride.

12. The solid oral pharmaceutical composition of any one of claims 1 or 3 - 9 , wherein the antiemetic is promethazine or a pharmaceutically acceptable salt thereof.

13. The solid oral pharmaceutical composition of any one of claims 1 , or 3 - 9 , wherein the antiemetic is promethazine hydrochloride.

14. The solid oral pharmaceutical composition of any one of claims 1 or 2 , wherein the antiemetic is promethazine or a pharmaceutically acceptable salt thereof, and is present in an amount of about 0.5-60 mg.

15. The solid oral pharmaceutical composition of any one of claims 1 - 5 , 7 or 8 , wherein the antiemetic is promethazine or a pharmaceutically acceptable salt thereof, and is present in an amount of about 12.5 mg.

16. The solid oral pharmaceutical composition of claim 1 , wherein the antiemetic is promethazine and is present in an amount of 11 mg.

17. The solid oral pharmaceutical composition of claim 15 , wherein the antiemetic is promethazine hydrochloride and is present in an amount of about 12.5 mg.

18. The solid oral pharmaceutical composition of any one of claims 1 - 9 , wherein the non-opioid analgesic is acetaminophen or a pharmaceutically acceptable salt thereof.

19. The solid oral pharmaceutical composition of any one of claims 1 - 9 , wherein the non-opioid analgesic is acetaminophen or a pharmaceutically acceptable salt thereof and is present in an amount of about 200-600 mg.

20. The solid oral pharmaceutical composition of any one of claims 1 - 5 , 7 or 8 , wherein the non-opioid analgesic is acetaminophen or a pharmaceutically acceptable salt thereof, and is present in an amount of about 325 mg.

21. The solid oral pharmaceutical composition of claim 1 , wherein the opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof, the non-opioid analgesic is acetaminophen or a pharmaceutically acceptable salt thereof, and the antiemetic is promethazine or a pharmaceutically acceptable salt thereof, which are present in a ratio by weight of about 1:43:1.7, respectively.

22. The solid oral pharmaceutical composition of claim 1 , wherein the opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof, the non-opioid analgesic is acetaminophen or a pharmaceutically acceptable salt thereof, and the antiemetic is promethazine or a pharmaceutically acceptable salt thereof, which are present in a ratio by weight of 1:43.33:1.67, respectively.

23. The solid oral pharmaceutical composition of claim 1 , wherein the opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof, the non-opioid analgesic is acetaminophen or a pharmaceutically acceptable salt thereof, and the antiemetic is promethazine or a pharmaceutically acceptable salt thereof, which are present in an amount of 6-8 mg, 200-350 mg, and 5-13 mg, respectively.

24. The solid oral pharmaceutical composition of claim 1 , wherein the opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof, the non-opioid analgesic is acetaminophen or a pharmaceutically acceptable salt thereof, and the antiemetic is promethazine or a pharmaceutically acceptable salt thereof, which are present in an amount of about 7.5 mg, about 325 mg, and about 12.5 mg, respectively.

25. The solid oral pharmaceutical composition of claim 1 , wherein the opioid analgesic oxycodone or a pharmaceutically acceptable salt thereof, the non-opioid analgesic is acetaminophen or a pharmaceutically acceptable salt thereof, and the antiemetic is promethazine or a pharmaceutically acceptable salt thereof, which are present in an amount of about 7.5 mg, about 325 mg, and about 12.5 mg, respectively.

26. The solid oral pharmaceutical composition of any one of claims 1 - 9 , 21 - 24 or 25 , wherein the solid oral pharmaceutical composition is a tablet.

27. The solid oral pharmaceutical composition of claim 26 , wherein the tablet is a bi-layer tablet.

28. The solid oral pharmaceutical composition of claim 1 , wherein the solid oral pharmaceutical composition further comprises an opioid antagonist or an additional agent for reducing abuse and/or diversion.

Assignments (3)
CHANGE OF ADDRESS Recorded Dec 9, 2015
From: LOCL PHARMA, INC.
To: LOCL PHARMA, INC.
Reel/Frame 037255/0606 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2015
From: BOSSE, PAUL
To: CHARLESTON LABORATORIES, INC.
Reel/Frame 035895/0546 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2015
From: CHARLESTON LABORATORIES, INC.
To: LOCL PHARMA, INC.
Reel/Frame 035895/0560 →
Continuity (6)
Continuation 14099432 · Dec 6, 2013
Continuation 12444521
Provisional Application 60948375 · Jul 6, 2007
Provisional Application 60921563 · Apr 3, 2007
Provisional Application 60850451 · Oct 9, 2006
Related Publication 20150328161A1 · Nov 19, 2015